Publications by authors named "C Bilato"
[ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].
G Ital Cardiol (Rome)
December 2024
Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a pivotal therapeutic agent in the management of the cardio-renal-metabolic continuum. Initially developed for glycemic control in type 2 diabetes mellitus, its benefits extend far beyond glucose regulation. Clinical trials have demonstrated semaglutide's potential to reduce major adverse cardiovascular events, particularly in overweight/obese patients with high cardiovascular risk, as well as improving functional capacity in patients suffering from heart failure with preserved left ventricular function.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness and tolerability of oral procainamide versus mexiletine for treating recurrent ventricular arrhythmias in patients who didn't respond to standard therapies like amiodarone and beta-blockers.
- Out of 68 patients treated, approximately 56% experienced a significant reduction in arrhythmia burden, with procainamide showing nearly three times higher efficacy compared to mexiletine.
- Side effects were noted in both treatments, but procainamide had a lower discontinuation rate due to severe side effects, suggesting it may be a preferable option for this patient group.
Article Synopsis
- * They are less likely to receive crucial procedures and effective medications, so assessing factors like frailty and other health conditions is vital for tailoring their care.
- * There is a lack of research on elderly individuals with ACS, making it critical for clinicians to develop targeted strategies to improve these patients' treatment and quality of life as the population ages.
Article Synopsis
- The study investigates the significance of cardiac troponin (cTn) levels in predicting mortality in patients with Takotsubo syndrome (TTS), analyzing data from the International Takotsubo Registry.
- It identifies that a cTn increase greater than 28.8 times the upper reference limit signals clinically relevant myocardial injury, correlating with a higher risk of mortality over 5 years (adjusted HR 1.58).
- The findings enhance understanding of patient risk profiles in TTS, emphasizing the need for increased monitoring and follow-up for those with significant troponin elevations.